Switzerland's Serono plans to buy the rights to a drug developed by Genmab for treatment of T-cell lymphoma, which is in late-stage development. One analyst said sales of the drug could amount to as much as $400 million a year, and that Serono appears to be intent on developing a group of treatments for diseases related to T cells.

Full Story:

Related Summaries